These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 9346370)

  • 21. Erythropoietin receptor mutations and Olympic glory.
    Longmore GD
    Nat Genet; 1993 Jun; 4(2):108-10. PubMed ID: 8348144
    [No Abstract]   [Full Text] [Related]  

  • 22. Erythropoietin: from mountain top to bedside.
    Erslev AJ; Caro J
    Adv Exp Med Biol; 1989; 271():1-7. PubMed ID: 2486278
    [No Abstract]   [Full Text] [Related]  

  • 23. [Erythropoietin: current aspects].
    Espinós D
    An R Acad Nac Med (Madr); 1993; 110(1):19-36; discussion 37-8. PubMed ID: 8238819
    [No Abstract]   [Full Text] [Related]  

  • 24. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.
    Bieber E
    J Reprod Med; 2001 May; 46(5 Suppl):521-30. PubMed ID: 11396386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythropoietin and its receptor: signaling and clinical manifestations.
    Cohen J; Supino-Rosin L; Barzilay E; Eisen-Lev R; Mittelman M; Neumann D
    Isr Med Assoc J; 2002 Nov; 4(11):1072-6. PubMed ID: 12489509
    [No Abstract]   [Full Text] [Related]  

  • 26. Erythropoietin 1997: a brief update.
    Gahl GM; Eckardt KU
    Perit Dial Int; 1997; 17 Suppl 2():S84-90. PubMed ID: 9163805
    [No Abstract]   [Full Text] [Related]  

  • 27. Erythropoietin and its use in renal failure.
    Sulková S; Krajhanzl A
    EDTNA ERCA J; 1996; 22(1):suppl 1-7; quiz 8. PubMed ID: 10723310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Case of early pronounced anemia and its effective treatment with human recombinant erythropoietin in a female patient with polycystic kidney in a conservative stage of chronic renal failure].
    Alekseeva TB; Nikolaev AIu; Trofimova EI
    Ter Arkh; 1999; 71(6):70-1. PubMed ID: 10420463
    [No Abstract]   [Full Text] [Related]  

  • 29. [Erythropoietin].
    Pagel H; Jelkmann W
    Dtsch Med Wochenschr; 1989 Jun; 114(24):959-63. PubMed ID: 2659306
    [No Abstract]   [Full Text] [Related]  

  • 30. Erythropoietin: induction of synthesis to signal transduction.
    Roberts D; Smith DJ
    J Mol Endocrinol; 1994 Apr; 12(2):131-48. PubMed ID: 8060478
    [No Abstract]   [Full Text] [Related]  

  • 31. Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects.
    Nissenson AR; Nimer SD; Wolcott DL
    Ann Intern Med; 1991 Mar; 114(5):402-16. PubMed ID: 1992884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anemia syndrome in patients with chronic renal insufficiency on peritoneal dialysis treated with recombinant erythropoietin].
    Romanova LA; Lugovskaia SA; Khareb F; Shumov EV; Shmarov DA
    Urologiia; 2002; (5):26-30. PubMed ID: 12402772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythropoietin in the critically ill: what is the evidence?
    Corwin HL; Eckardt KU
    Nephrol Dial Transplant; 2005 Dec; 20(12):2605-8. PubMed ID: 16221691
    [No Abstract]   [Full Text] [Related]  

  • 34. Brain protection by erythropoietin: a manifold task.
    Rabie T; Marti HH
    Physiology (Bethesda); 2008 Oct; 23():263-74. PubMed ID: 18927202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Erythropoietin in the treatment of heart failure and ischemia].
    Lewartowski B
    Kardiol Pol; 2007 Feb; 65(2):192-7. PubMed ID: 17366366
    [No Abstract]   [Full Text] [Related]  

  • 36. Novel erythropoiesis-stimulating agents: a new era in anemia management.
    Macdougall IC
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):200-7. PubMed ID: 18077782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The molecular physiology of erythropoietin and the erythropoietin receptor.
    Zhu Y; D'Andrea AD
    Curr Opin Hematol; 1994 Mar; 1(2):113-8. PubMed ID: 9371269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythropoietin-resistant refractory renal anemia: effects of oral L-carnitine supplementation.
    Kawabata M; Kasuga S; Hara H; Suyama S; Moriyama K; Takabatake T
    Clin Nephrol; 2001 Mar; 55(3):265-6. PubMed ID: 11316253
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-acting anemia management.
    Dykeman J
    CANNT J; 2002; 12(2):27-9. PubMed ID: 12164020
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.